ExpreS2ion Biotechnologies
Blood & Organ Banks · Denmark · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Agern Allé 1, Korsholm, North Denmark, 2...Phone Number
+45 22221019Website
www.expres2ionbio.comRevenue
$5.6 MillionIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
2
2
2
About ExpreS2ion Biotechnologies
ExpreS2ion Biotechnologies is a clinical-stage biotechnology company focused on developing innovative vaccines aimed at transforming healthcare and improving quality of life globally. Utilizing their proprietary ExpreS2 protein expression system, they are advancing groundbreaking vaccines to combat infectious diseases and treat cancer. Their lead product, ES2B-C001, is a novel HER2 cancer immunotherapy designed to generate a robust immune response and offer superior tumor inhibition. The company targets healthcare providers and patients in need of effective vaccine solutions.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ExpreS2ion Biotechnologies your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
ExpreS2ion Biotechnologies, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if ExpreS2ion Biotechnologies is spiking on competitors!
Check if ExpreS2ion Biotechnologies has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at ExpreS2ion Biotechnologies
Click to see if ExpreS2ion Biotechnologies had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when ExpreS2ion Biotechnologies launches new products
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on ExpreS2ion Biotechnologies recently announced quarterly report
Funding: Get notified immidiatlly once ExpreS2ion Biotechnologies has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
ExpreS2ion Biotechnologies is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
ExpreS2ion Biotechnologies is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about ExpreS2ion Biotechnologies.
ExpreS2ion Biotechnologies financials insights
Gather financial insights about ExpreS2ion Biotechnologies, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Stock Offering
$24.6M
ExpreS2ion Biotechnologies Tech Stack
A closer look at the technologies used by ExpreS2ion Biotechnologies
See more technologies
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Project
A high-level source in Accounting has indicated that the organization is in the midst of initiatives related to accounting analytics, cloud-based accounting software, financial close management, and payroll. ExpreS2ion Biotechnologies is currently evaluating vendors to support these efforts.The organization is considering the use of a contingent workforce to support these efforts. Microsoft Excel tools are being leveraged as part of these initiatives.
Analytics & Insights, IoT, Contingent Workforce, Accounting, Financial Planning, Compensation & Benefits, Financial Systems, Software, Finance
Pain Point
Project
A high-level source in Accounting has indicated that the organization is planning to remediate challenges related to departmental accounting and expense tracking. ExpreS2ion Biotechnologies is currently evaluating vendors to support these efforts.The organization will be increasing investments within the next six months. The organization plans to focus remediation efforts on developing a step-by-step instruction guide for employees.
Spending/Investment, IoT, Accounting, Financial Planning, Audit, Finance
Project
Accounting, Compensation & Benefits, Finance
ExpreS2ion Biotechnologies News & Media
Warrants of series TO 10 were exercised to approximately 69 percent and ExpreS2ion receives approximately SEK 10 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, RUSSIA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, 6 December 2024 - Today ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") announces the outcoExpreS2ion announces approval to initiate a Phase I clinical trial of ES2B-C001, its novel therapeutic vaccine, being developed for HER2-expressing breast cancer
Hørsholm, Denmark, 2 December 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion"), a clinical-stage biotechnology company with a focused portfolio of vaccine candidates targeting infectious diseases and cancer, is proud to announce the approval of its Phase I clinical trial application (CTA) by the Austrian Agency for Health and Food Safety for its novel therapeutic vaccine candidate, ES2B-C001, against HER2-expressing breast cancer. Bent U. Frandsen, CExpreS2ion publishes video presentations from Biostock Life Science Summit and Analysguiden Stora Aktiedagarna
Hørsholm, Denmark, 2 December 2024 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that filmed company presentations in which CEO Bent Frandsen shared insights into the company’s development strategy and value creation potential are now available on the company’s website. The first presentation was delivered at the Biostock Life Science Summit on 21 November 2024. The second took place at the Aktiespararna event Stora Aktiedagarna in StockholmLast day of trading in warrants of series TO 10 in Expres2ion Biotech Holding AB is today, 2 December 2024
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, RUSSIA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, 2 December 2024 - ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") announces that today is t
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ExpreS2ion Biotechnologies
Sign Up For FreeTo access detailed company insights
ExpreS2ion Biotechnologies is a clinical-stage biotechnology company focused on developing innovative vaccines aimed at transforming healthcare and improving quality of life globally. Utilizing their proprietary ExpreS2 protein expression system, they are advancing groundbreaking vaccines to combat infectious diseases and treat cancer. Their lead p... Read More
